Search - tctmd.com

Displaying 341 - 360 of 821

Sort: Relevancy | Date

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

Todd Neale

August 05, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

Marcus A. Banks

July 31, 2019

News Daily News

Bleeding, Myocardial Injury Are Key Drivers of Deaths After Noncardiac Surgery

Michael O'Riordan

July 29, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EuroPCR 2019

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

L.A. McKeown

May 31, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Michael O'Riordan

May 13, 2019

News Daily News

Staged, Complete PCI Beats Culprit Stenting Out to 5 Years in STEMI Patients

Caitlin E. Cox

May 10, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Daily News

PCI on the Rise Among the Elderly, Who Are Reaping Survival Gains

Caitlin E. Cox

April 23, 2019

News Daily News

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Michael O'Riordan

April 18, 2019

Advertisement

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Stroke After PCI: Rare but Rising as Patient Complexity Climbs

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

Bleeding, Myocardial Injury Are Key Drivers of Deaths After Noncardiac Surgery

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

New Clarity on Patients at High Risk for Bleeding After PCI

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Bariatric Surgery Linked to Survival Advantage After MI and CVA

Staged, Complete PCI Beats Culprit Stenting Out to 5 Years in STEMI Patients

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

PCI on the Rise Among the Elderly, Who Are Reaping Survival Gains

Help, Not Harm: Omega-6 PUFAs Linked With Lower Risk of CVD Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content